Summary:
- Daiichi Sankyo, a pharmaceutical company, has announced the development of a new fixed-dose combination tablet that aims to lower LDL-C (bad cholesterol) levels.
- The tablet combines three different cholesterol-lowering medications, which can help address the persistent challenges in managing high LDL-C levels in patients.
- This new treatment option could provide a more convenient and effective way for patients to manage their cholesterol and reduce their risk of heart disease.